Adstiladrin
(Adebrelimab)Phase 3Monoclonal antibody
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Adebrelimab is used to treat certain types of cancer, specifically a blood cancer called diffuse large B-cell lymphoma (DLBCL), by helping the immune system recognize and attack cancer cells.[1] Adstiladrin is currently being investigated across 53 indications[3], with its most advanced program in Phase 3.[1]
Adstiladrin is one of 881 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
53
Indications
123
Total Trials
119
Active Trials
880
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 53 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adstiladrin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer8 trials
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Recruiting·—·Phase 2·NCT06418594·30 enrolled
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06470633·29 enrolled
Show 5 more trials
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
Not yet recruiting·—·Phase 2·NCT07317778·249 enrolled
PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer
Not yet recruiting·—·Phase 2·NCT06842472·70 enrolled
Pancreatic Cancer7 trials
Show 4 more trials
Patients With Advanced Solid Tumors6 trials
Small Cell Lung Cancer6 trials
Hepatocellular Carcinoma6 trials
56 more indications
Esophageal Cancer5 trials
Show 2 more trials
Comparing Induced Chemoimmunotherapy Followed By Concurrent Chemoradiotherapy And Concurrent Chemoradiotherapy Followed By Immunotherapy In Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07733830·120 enrolled
Biliary Tract Cancer4 trials
Neoadjuvant Therapy4 trials
Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
Not yet recruiting·—·Phase 2·NCT07035392·32 enrolled
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06684158·70 enrolled
Metastatic Colorectal Cancer4 trials
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
Recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·Phase 2·NCT06282445·36 enrolled
Show 1 more trial
A Multicenter, Prospective, Phase II Exploratory Study on the First-line Treatment of MSS/ PMMR-type Advanced Colorectal Cancer With Adebrelimab Combined With Simvastatin and Targeted and Chemotherapy
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07718490·43 enrolled
Non-Small Cell Lung Cancer4 trials
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT07031154·43 enrolled
Esophageal Squamous Cell Carcinoma3 trials
Advanced Solid Tumors3 trials
Gastric Cancer3 trials
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06385873·32 enrolled
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
Not yet recruiting·—·Phase 2·NCT06881017·140 enrolled
Biliary Tract Neoplasms3 trials
Nasopharyngeal Carcinoma2 trials
Concurrent Chemoradiotherapy2 trials
First-line Treatment2 trials
Gastroesophageal Junction Adenocarcinoma2 trials
Colorectal Cancer2 trials
An Open, Multicenter Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
Active, not recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 2·NCT07071714·103 enrolled
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 2·NCT07071714·103 enrolledUrothelial Carcinoma2 trials
Intrahepatic Cholangiocarcinoma2 trials
Chemoradiotherapy2 trials
Chemotherapy2 trials
Ovarian Cancer2 trials
Prostate Cancer1 trial
Triple-Negative Breast Cancer1 trial
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
Not yet recruiting·—·Phase 2·NCT06229067·182 enrolled
Head and Neck Squamous Cell Carcinoma1 trial
Hypofractionated Radiotherapy1 trial
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06914050·30 enrolled
Oral Squamous Cell Carcinoma1 trial
Rectal Adenocarcinoma1 trial
Conversion Therapy1 trial
Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer
Recruiting·—·Phase 2·NCT07353684·49 enrolled
Small Cell Carcinoma1 trial
A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma
Not yet recruiting·—·Phase 2·NCT06478264·40 enrolled
Microwave Ablation1 trial
A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors
Not yet recruiting·—·Phase 2·NCT06537505·60 enrolled
Pancreatic1 trial
Bladder Carcinoma1 trial
Unresectable Biliary Tract Carcinoma1 trial
Oligometastatic1 trial
Lung Cancer1 trial
Malignancies1 trial
Surufatinib1 trial
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06375642·30 enrolled
Cervical Cancer1 trial
Soft Tissue Sarcoma1 trial
Capecitabine1 trial
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
Recruiting·—·Phase 1/2·NCT06776770·52 enrolled
Efficacy and Safety1 trial
Solid Tumors1 trial
Neoadjuvant Treatment1 trial
Adebrelimab Neoadjuvant Treatment for Resectable ESCC
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT07388095·22 enrolled
Pancreatic Ductal Adenocarcinoma (PDAC)1 trial
Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer
Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT07827053·36 enrolled
Carcinoma, Non-Small-Cell Lung1 trial
Locally Advanced Cervical Cancer1 trial
Glioblastoma1 trial
NSCLC1 trial
GC/GEJC1 trial
Cervical Neoplasms1 trial
A Single-arm, Phase II Study of Short-course Hypofractionated Radiotherapy Combined With Adebrelimab and Single-agent Platinum Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07731828·35 enrolled
Lung1 trial
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Adebrelimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details